How compassionate use enabled Israel to deliver the Pfizer-BioNTech COVID-19 vaccination to vulnerable children aged 12-15 years before regulatory approval.

Michal SteinZachi GrossmanTal Brosh-NissimovBat-Sheva GottesmanArnon ShaharEfrat WechslerEran MatzOrna CohenSharon Alroy-PreisEmilia Anisnull null

Published in: Acta paediatrica (Oslo, Norway : 1992) (2021)

The emergency use of COVID-19 vaccination for 333 adolescents aged 12-15, 92 of them with 2 doses, based on a position paper and compassionate treatment regulations, did not result in any adverse effects. Since 27 July 2021, the same process was further applied in Israel among younger children, aged 5-11, preceding formal release of the clinical trial.

Keyphrases

coronavirus disease
sars cov
young adults
clinical trial
emergency department
public health
physical activity
transcription factor
respiratory syndrome coronavirus
study protocol
phase ii
phase iii
drug administration